Inflammatory bowel disease (IBD) is a crowded drug market with plenty of treatment options across the two forms of the ...

Q3 2025 Earnings Call Transcript November 4, 2025 Rigel Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $1 ...

To address the specific challenges faced by older adults with inflammatory bowel disease (IBD), UCSF Health created the UCSF ...

GLP-1RA use, compared with basal insulin and DPP-4i use, was associated with lower risks for IBD and hospitalization in type 2 diabetes.

Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD) are often confused but are distinct conditions. IBS is a functional disorder causing discomfort without lasting damage, while IBD ...

This cloud communications company is witnessing an uptick in its growth trajectory thanks to the growing adoption of AI tools ...

Teva Pharmaceutical Industries Ltd (TEVA) reports its 11th consecutive quarter of growth, driven by innovative products, ...